Matt Caspari (@deeptechvc) header
Matt Caspari (@deeptechvc) profile picture

Deep Tech VC 🚀 | Managing Partner @alumniventures | 2x Founder CEO | Ex-Innovation @Nike 👟 | @georgetown @berkeleyhaas 📚 | Opinions mine.

Palo Alto, CA
Joined August 2013
Photo by Matt Caspari (@deeptechvc)Photo by Matt Caspari (@deeptechvc)Photo by Matt Caspari (@deeptechvc)Photo by Matt Caspari (@deeptechvc)Photo by Matt Caspari (@deeptechvc)Photo by Matt Caspari (@deeptechvc)Photo by Matt Caspari (@deeptechvc)Photo by Matt Caspari (@deeptechvc)Photo by Matt Caspari (@deeptechvc)Photo by Matt Caspari (@deeptechvc)
Matt Caspari retweeted
Today, we are excited to introduce Ladon, a state-of-the-art biological foundation model that predicts disease trajectory and treatment response in patients. There is immense complexity in the individual biology of every patient. Two patients can have the same diagnosis and receive the same treatment, yet have very different outcomes: one responds well and lives for years, while the other’s disease continues to progress. Understanding and resolving this heterogeneity to predict outcomes is how we accelerate our delivery of medicines for patients and unlock clinical trial abundance. Ladon is our first step towards this future: one where we can learn more from every patient enrolled so that we can run smaller, faster trials with higher success rates. We built it to give drug developers quantitative support on billion-dollar clinical trial decisions. Today we're excited to share Ladon's capabilities in our blog and technical report. Ladon is a 3B parameter model trained on millions of RNA-seq samples spanning decades of technical and biological variation across tissues and species. Ladon beats gene expression baselines, established biomarkers, and existing RNA foundation models at predicting patient prognosis and therapeutic response in 140+ oncology tasks, including external validation on past clinical trials. This is significant because clinical trials are fundamentally generalization problems. We show that Ladon-derived predictions are robust across indications, treatments, and sequencing platforms. Reach out if you’d like to get started with the model today! Read more about Ladon in the blog: blank.bio/introducing-ladon Find more technical details in the white paper: blank.bio/introducing-ladon
44
125
23
608
49,430
When Intelligence Is Free, What Gets Expensive? 🧠 I make investments with a five-to-10-year horizon, so I’m investing for a post-AGI world. The highlight: the cost of a given level of AI capability is falling roughly 50x per year. As cheap intelligence eats the digital world, the physical world becomes the scarce, valuable thing — energy, robots, regulatory approvals, and skilled people who can build and fix real systems. Full blog below with the data and where we are investing in Physical AI, Healthcare, and Energy.👇
1
1
207
Matt Caspari retweeted
Robotics are supposed to be a step change in labor economics. To actually deliver that you have to completely change the cost curve. Fully vertically integrated. Purpose-built robotics. Not humanoids. We’ve done that at @cytronic_ai ~80% lower cost and facilities that run 24/7. Thanks @alex @twistartups for having me on.
1
3
1
10
2,170
Matt Caspari retweeted
We're pulling back the curtain on our aircraft on 14 Sept at @AFA_Air_Space's Air, Space & Cyber Conference next month. See you there.
9
22
11
66
4,517
Matt Caspari retweeted
Today, we are announcing our $31M seed financing at Apollo Atomics. The $26M equity is led by FCVC with participation from Y Combinator, TeleSoft Partners, Alumni Ventures, Pelion Venture Partners, Duke Capital Partners, Robinhood Ventures, and Nucleation Capital. $5M of equipment financing is provided by Oak Ridge Financial. Apollo Atomics is the only nuclear company that can deliver high power output nuclear reactors (>80 MW) on a truck. The higher power density is the strongest argument for cost effectiveness and mass manufacturing in the nuclear industry today. We achieve this without relying on exotic/scarce fuel, unqualified materials, or high regulatory uncertainty. Achieving that goal is a mirage if you don’t build the right company. With Drew Walker, we have assembled an extremely talent dense team with Excellence, Intensity, and Execution at its core. We are running a low power reactor demonstrator within MIT and now building a full scale 1 MW reactor prototype under commercial reactor conditions. We work directly with the U.S. Nuclear Regulatory Commission to support a commercial deployment in 2028. Apollo Atomics is not hardware in vacuum, we are building software solutions for autonomous reactor control, licensing support, and reactor modeling to reduce OpEx and deployment timeline. Deeply grateful to our early investors for supporting our mission when no one else believed particularly Genesis Fund, Arjun Gupta, and New Era Ventures, to our early supporters within Massachusetts Institute of Technology, MIT Sandbox Innovation Fund Program, TNT, MIT Department of Nuclear Science and Engineering. Excited to have many brilliant individual investors supporting our mission including Paul Graham, Evan Meagher, CFA, Philip Johnston, Ray Rothrock, Matteo Franceschetti
34
40
27
302
112,108
Matt Caspari retweeted
Had a great conversation with @alex Wilhelm on @twistartups about what we’re building at @cytronic_ai. We went deep on the economics of physical AI, why traditional fulfillment gets more expensive as it scales, and how robotics can fundamentally change the cost curve. A typical 3PL charges ~$3–$3.50 to fulfill an order. At Cytronic, that same order can be ~$0.70. And fulfillment is only the beginning. Full conversation: youtube.com/watch?v=qW9wdH8_…
4
7
1
19
7,339
Matt Caspari retweeted
Excited to announce @andromedasurg's Series A led by @Standard_Cap. Could not imagine a better partner as we bring autonomous surgery to the world. We raised $15M in this round and $30M in total. We are launching now and you will be hearing a lot more from us soon!
Announcing our $15 million Series A, led by @Standard_Cap with participation from @ycombinator, @Vox_Capital, and other notable funds and angels. This brings our total funding to $30 million. We’re building an autonomous surgery platform to give every patient access to the world’s best surgeon. It’s like a sous chef for surgery. The surgeon sets the plan and the platform executes. Surgeons have successfully treated 44 patients with our product so far. This round will fund initial launch and initial scale-up. We're cleared to launch in New Zealand and Canada, with more clearances expected soon. Surgery is a $3.7 trillion global market, and a better application for autonomy than driving. But while autonomous vehicles are already widespread on public roads, most surgical robots have very limited intelligence. That changes now. Surgery will soon become one of the most important applications of physical AI. Andromeda is ready to lead the way. svpost.com/articles/andromed…
21
25
7
94
41,279
Matt Caspari retweeted
We believe brands shouldn't have to become Amazon to ship like Amazon. Today, we’re unveiling @cytronic_ai, a robotic fulfillment network helping ecommerce brands lower costs by up to 80%, deliver faster, and scale without giving up control of their customers.
4
6
2
38
7,071
Matt Caspari retweeted
Brands shouldn't have to become Amazon to ship like Amazon. Today we're unveiling @cytronic_ai — robotic fulfillment that helps ecommerce brands lower costs by up to 80%, deliver faster, and scale without giving up control of their customers.
59
56
21
710
890,801
Tech Weekend June 2026 Recap: VC Panel: How VCs Make Decisions — From First Meeting to Term Sheet. @mat Gary Gardner, Founder & CEO of Lead Generation Hubs, moderated the session with a simple premise: most fundraising decisions are made in rooms founders never see, and a "no" often has far less to do with the pitch than with everything happening around it. The hour was about making that hidden process visible. Matt Caspari (@deeptechvc) Managing Partner at @alumniventures, leads the firm's Deep Tech and Strawberry Creek Ventures funds and invests from seed to pre-IPO. Having raised over $100M as a two-time founder himself, he walked the room through what actually happens inside the partnership meeting after you leave. His takeaway for founders was about the Champion: your real job in the room is to give the partner who believes in you everything they need to defend the deal when you're no longer there to do it yourself. Victoria Smith, Partner at @ZacuaVentures, focused on the earliest stages across PropTech, ConTech, and AI-native software. Bringing both an operator's and an investor's lens, she helped founders decode investor feedback that isn't direct — what "keep us posted" really signals — and how to run a process so multiple investors move at the same time. Her message was about Momentum: a round comes together when interest is concurrent, not when it's chased one conversation at a time. Allen Smith, Founder & Managing Partner at Musa Capital, invests in tech-enabled businesses built by diverse founding teams and brings a decade in go-to-market from LinkedIn and Microsoft. He spoke to what investors decide about you before you ever start pitching, and offered a practical playbook for international founders on how to set up, position, and build credibility when raising in the US market. From there the session moved into the term sheet — what genuinely matters to negotiate and what founders tend to over-index on. The panel's shared view was that the negotiation itself is the first real test of the partnership: how you handle it signals how you'll work together long after the money is in the bank. Thank you to Matt Caspari, Victoria Smith, Allen Smith, and Gary Gardner for pulling back the curtain on how venture decisions really get made, and for giving our founders the tactical tools to navigate the path to a "yes." Tech Weekend returns September 10–11, 2026 with more conversations like this one. Details and sign up at techweekend.org
1
1
6
629
Deep Tech Eats VC 🚀 Two years after publishing "Why Deep Tech Is Eating Venture Capital," Sam Vatcha and I went back to the thesis and looked at the latest data. The highlight: deep tech has jumped from ~20% of global VC funding two years ago to 36% today — and it's still accelerating. Full blog below with the data and our thoughts on opportunities in Defense, Energy, and Semiconductors.
1
4
839
🚨 SF Deep Tech Week event! We're hosting The Future Is Built with our friends from @BoostVC , @DCVC , @VenturesVc , and @RadicalVentures . Meet deep tech startups across 🤖 Robotics, 🧠 AI Infrastructure, 🛡️ Defense, ⚡ Energy, 🚀 Space, and more... ⏰ 5 to 8 PM on Wednesday June 24 Request to attend 👇
1
1
106
Coming up at Tech Weekend June 2026: VC Panel: How VCs Make Decisions — From First Meeting to Term Sheet What really happens on the other side of the table when you're raising. This session covers: • What VCs decide about you before you start pitching • Why most good meetings don't turn into checks — and what changes that • What happens inside the partnership meeting after you leave the room • How to run a process so multiple investors move at the same time • How to read investor feedback when they're not being direct • What to negotiate on a term sheet, and what doesn't matter • For international founders: how to set up, position, and raise in the US Meet the Speakers 🎤 Matt Caspari @deeptechvc — Managing Partner, @alumniventures Investment Focus: Deep Tech from seed to pre-IPO Matt leads the Deep Tech and Strawberry Creek Ventures funds at Alumni Ventures, backing mission-driven founders across agriculture, AI, aviation, biotech, defense, energy, longevity, robotics, and space. A two-time venture-backed founder/CEO — including founding CEO of Aurora Biofuels (100+ employees, $100M+ raised, acquired by Reliance Industries) — and a former leader on Nike's innovation team. 🎤 Victoria Smith — Partner at @ZacuaVentures Investment Focus: PropTech, ConTech, AI-native software, marketplaces, consumer & enterprise SaaS Victoria was an early hire at both Jackson Square Ventures and Zacua Ventures, where she led pre-seed investments in software for the built environment and ran Launchpad, JSV's earliest-stage vehicle for student-led startups. A former founder of an acquired company herself, she brings both the operator's and the investor's perspective to the table. 🎤 Allen Smith — Founder & Managing Partner, @Musa_Capital Investment Focus: Early-stage, tech-enabled businesses built by diverse founding teams Allen is Founder and Managing Partner at Musa Capital, an early-stage firm investing in diverse founding teams building tech-enabled businesses. He brings 10+ years in go-to-market and sales operations from LinkedIn, Microsoft, and Waterstone Management Group, where he built and scaled major commercial initiatives. Moderator 🎤 Gary Gardner — Founder & CEO, Lead Generation Hubs Gary is a seasoned sales leader and Army Reserve Captain building a platform to empower sales professionals. With a PhD in Organization and Management and experience leading high-performing teams as VP of Sales at Hyqoo and Toptal, he brings both academic and practical expertise to business development. 📅 Date & Time: Thursday, June 18, 2026 | 10:00 AM – 11:00 AM 📍 Location: 75 Arbor Road, Menlo Park, CA Who should attend? If you're fundraising now — or about to start — and want to understand how investors actually decide, from the first meeting through the partnership discussion to the term sheet, this session is for you. International founders raising in the US will find it especially useful. Details and sign up at: techweekend.org
2
1
2
181
Matt Caspari retweeted
With a nod to @leopoldasch, we're releasing Biological Awareness - our musings on the next decade at the frontiers of AI and life sciences. Six ideas we explore: → Task-specific experimental tokens are the new gold in biology → Bio AI data factories will pioneer new business models → Smoothing out the jagged frontier for pharma enterprises is where fortunes will be made → Clinical trial intelligence will be financialized before it is operationalized → The bioweapons threat is real, accelerating, and underpriced → The BIOSECURE Act will fundamentally reshape supply chains 2026 marks ten years of Obvious investing at this intersection. A lot has happened. Even more is coming. Big thanks to: @kyosu, @syntenyAI, @GabriCorso, @inductivebio, @mithrl_ai , @instancebio , @strangemonad, @exnx and many others for their help!
11
37
9
457
114,804